KalVista Pharmaceuticals, Inc. Common Stock
Here’s whether KalVista Pharmaceuticals, Inc. Common Stock (KALV) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+7.64% over 10 days); strong 1-year return of +96.0%; 3-month momentum positive (+65.4%); rising volume confirms the move (2.39x 30d avg). Concerns: RSI 74 — overbought, elevated pullback risk. Currently 0.4% off its 52-week high. Score: +6/7.
KALV is in a confirmed uptrend, trading above both its 50-day ($18.59) and 200-day ($15.07) moving averages. With an RSI of 74.4, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of +96.0% compares to +27.9% for SPY (beat the market by 68.1%).